A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis.

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis.
复制标题

纤维化前骨髓纤维化患者生存预测和事件监测的多状态模型。

DOI:
10.1038/s41408-020-00368-1
复制
发表时间:
2020-10-14
影响因子:
12.8
通讯作者:
Barbui T
Barbui T
中科院分区:
医学1区
文献类型:
--
作者:
Carobbio A;Guglielmelli P;Rumi E;Cavalloni C;De Stefano V;Betti S;Rambaldi A;Finazzi MC;Thiele J;Vannucchi AM;Tefferi A;Barbui T

文献摘要

参考文献

被引文献

相似文献

在 382 名 WHO 定义的前纤维化骨髓纤维化 (pre-PMF) 患者中,随访时间中位数为 6.9 年,其中纤维化或白血病转化或死亡分别占病例的 15%、7% 和 27%。应用多状态模型来分析生存数据,考虑到 PMF 前临床过程的一部分的中间状态,包括明显的 PMF 和急性髓系白血病 (AML)。在这个多状态框架内,多变量模型揭示了年龄较大(> 65岁)和白细胞增多(> 15 × 109/L)作为死亡和白血病转化的预测因素。纤维化进展的危险因素包括贫血和 1 级骨髓纤维化。结果进一步受到高分子风险 (HMR) 的影响,但不受驱动突变的影响。分别有 15.2%、4.7% 和 17.3% 的患者直接转变为明显的 PMF、AML 或死亡。 AML 的风险在前 5 年最高 (7%),但此后趋于平稳。相反,随着时间的推移,明显的 PMF 或 AML 导致的死亡概率增加得更快,特别是与没有疾病进展的 PMF 前状态的死亡相比。 PMF 前状态下的存活概率在 10 年和 20 年分别降至 70% 和 30%。这项研究重点介绍了 PMF 前期的临床病程和疾病进展的估计。
Among 382 patients with WHO-defined prefibrotic myelofibrosis (pre-PMF) followed for a median of 6.9 years, fibrotic or leukemic transformation or death accounts for 15, 7, and 27% of cases, respectively. A multistate model was applied to analyze survival data taking into account intermediate states that are part of the clinical course of pre-PMF, including overt PMF and acute myeloid leukemia (AML). Within this multistate framework, multivariable models disclosed older age (>65 years) and leukocytosis (>15 × 109/L) as predictors of death and leukemic transformation. The risk factors for fibrotic progression included anemia and grade 1 bone marrow fibrosis. The outcome was further affected by high molecular risk (HMR) but not driver mutations. Direct transition to overt PMF, AML, or death occurred in 15.2, 4.7, and 17.3% of patients, respectively. The risk of AML was the highest in the first 5 years (7%), but leveled off thereafter. Conversely, the probability of death from overt PMF or AML increased more rapidly over time, especially when compared to death in the pre-PMF state without disease progression. The probability of being alive with pre-PMF status decreased to 70 and 30% at 10 and 20 years, respectively. This study highlights the aspects of the clinical course and estimates of disease progression in pre-PMF.
DOI: 10.1182/blood-2009-03-209262
发表时间: 2009-07-30
期刊: BLOOD
影响因子: 20.3
作者:
Vardiman, James W.;Thiele, Juergen;Bloomfield, Clara D.
通讯作者: Bloomfield, Clara D.
预纤维化的骨髓纤维化沿临床和生物连续体排列的证据,具有原发性骨髓纤维化。
DOI: 10.1371/journal.pone.0035631
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Barosi G;Rosti V;Bonetti E;Campanelli R;Carolei A;Catarsi P;Isgrò AM;Lupo L;Massa M;Poletto V;Viarengo G;Villani L;Magrini U
通讯作者: Magrini U
DOI: 10.1038/s41408-018-0054-y
发表时间: 2018-02-09
影响因子: 12.8
作者:
Barbui T;Thiele J;Gisslinger H;Kvasnicka HM;Vannucchi AM;Guglielmelli P;Orazi A;Tefferi A
通讯作者: Tefferi A
DOI: 10.1016/0304-4076(81)90071-3
发表时间: 1981-01-01
影响因子: 6.3
作者:
AKAIKE, H
通讯作者: AKAIKE, H
DOI: 10.1038/leu.2013.119
发表时间: 2013-09-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Vannucchi, A. M.;Lasho, T. L.;Tefferi, A.
通讯作者: Tefferi, A.